Top Industry Leaders in the Hyperhidrosis Treatment Market
Revance Therapeutics, a pioneer in the field, receives FDA approval for Qbrexza (glycopyrronium) cloth wipes, the first once-daily topical treatment for excessive underarm sweating in adults. This non-invasive option offers a convenient and effective solution for many patients.
Dermira, another key player, announces positive results from a Phase 3 trial of DRM04, a topical cream for axillary hyperhidrosis. This new option, if approved, could expand treatment options for patients seeking non-surgical solutions.
Botanix Pharmaceuticals expects to resubmit its New Drug Application (NDA) for BTXA, a topical botulinum toxin A treatment for underarm hyperhidrosis, in the first quarter of 2024. This potential market entrant could offer a longer-lasting alternative to existing topical options.
List of Hyperhidrosis Treatment Key Companies in the Market
-
Brickell Biotech Inc. (US)
-
Allergan PLC (Ireland)
-
Cynosure (US)
-
Dermira Inc. (US)
-
Dermadry Laboratories inc. (Canada)
-
GlaxoSmithKline PLC (UK)
-
Sesderma (Spain)
-
Miramar Labs Inc. (US)
-
Ulthera Inc. (US)